A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Name: A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Published: 2024
License: Public Domain

Janssen Research & Development, LLC · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

colorectal-neoplasms

colorectal neoplasms, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Related documents